OBJECTIVE: To compare the incidence and severity of acute cwellular rejection (ACR) between living donor liver transplantation (LDLT) and cadaveric liver transplantation (CLT). METHODS: 51 patients underwent LDLT among which 30 received the liver of blood-related donors, and 65 patients underwent CLT. Clinical data, such as the cold ischemic time of liver graft, use of immunosuppressive agents, ACR rate, response to steroid therapy, HLA matching between donor and recipient, and survival rates of liver graft and patients were collected and analyzed. RESULTS: The graft survival rate, patient survival rate, ACR rate, ACR multiple incidence rate, and no response rate to steroid therapy in CLT and LDLT groups were 72% vs 78%, 77% vs. 78%, 48% vs...
Objective This study was performed to identify risk factors for acute cellular rejection after liver...
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized tri...
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized tri...
Living donor liver transplantation (LDLT) may have better immunological outcomes compared to decease...
Living donor liver transplantation (LDLT) may have better immunological outcomes compared to decease...
PubMed ID: 16797325Living donor liver transplantation (LDLT) is a good alternative to cadaveric live...
WOS: 000238700500060PubMed ID: 16797325Living donor liver transplantation (LDLT) is a good alternati...
Background: The influence of lymphocytotoxic cross-match results on acute cellular rejection in adul...
BACKGROUND/AIMS: The number of people undergoing living donor liver transplantation (LDLT) has incre...
INTRODUCTION: As we have learned, there are no golden rules of immunosuppression in solid organ tran...
INTRODUCTION: As we have learned, there are no golden rules of immunosuppression in solid organ tran...
The number of people undergoing living donor liver transplantation (LDLT) has increased rapidly in m...
The different choices of immunosuppression (IS) regimens influenced the outcomes of liver transplant...
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized tri...
Background: Hypothetical studies that favour living donor liver transplantation (LDLT) for early hep...
Objective This study was performed to identify risk factors for acute cellular rejection after liver...
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized tri...
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized tri...
Living donor liver transplantation (LDLT) may have better immunological outcomes compared to decease...
Living donor liver transplantation (LDLT) may have better immunological outcomes compared to decease...
PubMed ID: 16797325Living donor liver transplantation (LDLT) is a good alternative to cadaveric live...
WOS: 000238700500060PubMed ID: 16797325Living donor liver transplantation (LDLT) is a good alternati...
Background: The influence of lymphocytotoxic cross-match results on acute cellular rejection in adul...
BACKGROUND/AIMS: The number of people undergoing living donor liver transplantation (LDLT) has incre...
INTRODUCTION: As we have learned, there are no golden rules of immunosuppression in solid organ tran...
INTRODUCTION: As we have learned, there are no golden rules of immunosuppression in solid organ tran...
The number of people undergoing living donor liver transplantation (LDLT) has increased rapidly in m...
The different choices of immunosuppression (IS) regimens influenced the outcomes of liver transplant...
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized tri...
Background: Hypothetical studies that favour living donor liver transplantation (LDLT) for early hep...
Objective This study was performed to identify risk factors for acute cellular rejection after liver...
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized tri...
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most randomized tri...